[go: up one dir, main page]

Matheus et al., 2006 - Google Patents

Risk factors for pancreatic fistula. Does it have a clinical application for early identification of patients with high risk to develop pancreatic fistula after …

Matheus et al., 2006

Document ID
4359496451813827036
Author
Matheus A
Montagnini A
Jukemura J
Jureidini R
Perini M
Penteado S
Haddad L
Abdo E
Cunha J
Publication year
Publication venue
Pancreas

External Links

Snippet

Methods: Thirty-seven patients who underwent PD at our hospital between January 2004 and July 2005 were reviewed retrospectively. The primary diseases of the patients included pancreas cancer, ampullary cancer, bile duct cancer, islet cell cancer, duodenal cancer …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Angst et al. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer
Lankisch et al. The natural course of acute idiopathic pancreatitis
Matheus et al. Risk factors for pancreatic fistula. Does it have a clinical application for early identification of patients with high risk to develop pancreatic fistula after pancreaticoduodenectomy?
Barreda et al. One Stage Necrosectomy: A useful technique for treating pancreatic necrosis
Ruthenbürger et al. The role of pancreatic phospholipase A2 in experimental pancreatitis
Bihalskyy et al. Oxidative stress and liver dysfunction in acute pancreatitis
Wittel et al. Severe necrotizing pancreatitis in mice induced by retrograde taurocholate infusion into the common bile duct
Garatea et al. Solid pseudopapillary neoplasm of the pancreas: report of 31 resected cases and description of a paradoxical inverse relation between age and tumor size
Balakrishnan et al. Comparison of drinking patterns in alcoholic chronic pancreatitis and alcoholic liver cirrhosis patients in India
Fujita et al. Early histological findings of mucinous cystic neoplasm of the pancreas (MCN): a case report
Hill et al. Dysregulated cMet down regulation in pancreatic adenocarcinoma cells
Haynatzki et al. Genetic anticipation in pancreatic cancer: Comparison of statistical tests
Cho et al. Keratinocyte growth factor and its receptor correlate with venous invasion via matrix metalloproteinase-9 (MMP-9) in pancreatic cancer
Fernandez-Zapico A defined survival pathway underlies the critical effects of Hedgehog on pancreatic carcinogenesis
Badalov et al. Drug-induced acute pancreatitis: An evidence based approach
Gasiorowska et al. Frequency of cationic trypsinogen (PRSS1) gene and the serine protease inhibitor, kazal type 1 (SPINK1) gene mutations in patients with chronic alcoholic pancreatitis (CAP)
Cavestro et al. MCP1 genotype in acute pancreatitis
Hackert et al. Exogenous capsaicin application induces endogenous CGRP liberation and attenuates acute experimental pancreatitis
Lugea et al. Plasminogen activating system in cultured pancreatic stellate cells: Effects of ethanol
Criddle et al. Comparative effects of cholecystokinin-58 and cholecystokinin-8 on calcium signalling in mouse pancreatic acinar cells
Hartwig et al. A new non-invasive model of necro-hemorrhagic pancreatitis in rats: Histomorphologic and pathogenetic characterization
Arumugam et al. Cromolyn blocks S100P activation of rage and improves gemcitabine effectiveness in pancreatic cancer
Brand et al. Feasibility of using biophotonics to assist in cytologic diagnosis of pancreatic cancer
Hegyi et al. The effects of trypsin on pancreatic PAR-2 receptors
Bredebusch et al. CYTOTOXIC EFFECTS OF TAXOL ON PANCREAS TUMOUR CELLS